Prognostic factors for survival of stage I nonsmall cell lung cancer patients: A population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003

Cancer

Volumn 110, Issue 7, 2007, Pages 1532-1541

  Ou, S H Ignatius ^a,b,c   Zell, Jason A ^a,b   Ziogas, Argyrios ^b   Anton Culver, Hoda ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bronchioloalveolar carcinoma; Epidemiology; Histologic grade; Mortality risk; Nonupper lobe tumor locations; Socioeconomic status; Stage I nonsmall cell lung cancer

Indexed keywords

ADULT; ARTICLE; CALCULATION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; ETHNICITY; FEMALE; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; LOBECTOMY; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; RISK FACTOR; SOCIOECONOMICS; SURVIVAL RATE; TUMOR VOLUME; UNITED STATES;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; ASIAN AMERICANS; CALIFORNIA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 34648830554     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22938     Document Type: Article

References (36)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
2. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tobacco Control. 2006;15:345-347.
3. The International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT scanning. N Engl J Med. 2006;355:1763-1771.
4. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with resected non-small cell lung cancer. N Engl J Med. 2004;350:351-360.
6. Winston T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:2589-2597.
7. Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7:719-727.
8. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713-1721.
9. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol. 2006;24(18 suppl):366S. Abstract 7008.
10. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2006;24(18 suppl):365S. Abstract 7007.
11. Fry WA, Philips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867-1876.
12. Cancer Reporting in California. Volume 1: Abstracting and Coding Procedures for Hospitals. Emeryville, Calif: California Tumor Registry, Department of Health Services, Cancer Surveillance Section; 1986.
13. Zell JA, Ou S-HI, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol. 2005;23:8396-8405.
14. Zell JA, Ou S-HI, Ziogas A, et al. Long-term survival difference for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol. 2006;17:1255-1262.
15. Parikh-Patel A, Bates JH, Campleman S. Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000. Cancer. 2006;107(5 suppl):1189-1195.
16. Sun Z, Aubry M-C, Deschamps C, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovascular Surg. 2006;131:1014-1020.
17. Iwasaki A, Shirakusa T, Enatsu S, et al. Is T2 non-small cell lung cancer located in left lower lobe appropriate to upstage? Interact Cardiovasc Thorac Surg. 2005;4:126-129.
18. Jones DR, Daniel TM, Denlinger CE, et al. Stage IB non-small cell lung cancers: are they all the same? Ann Thorac Surg. 2006;81:1958-1962.
19. Ichinose Y, Kato H, Koike T, et al. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg. 2001;122:803-808.
20. Kotoulas CS, Foroulis CN, Kostikas K, et al. Involvement of lymphatic metastasis spread in non-small cell lung cancer according to the primary cancer location. Lung Cancer. 2004;44:183-191.
21. Cerfolio RJ, Bryant AS. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall cell lung cancer. Ann Thorac Surg. 2006;81:1969-1973.
22. Rocha AT, McCormack M, Montana G, et al. Association between lower lobe location and upstaging for early-stage non-small cell lung cancer. Chest. 2004;125:1424-1430.
23. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Ann Thorac Surg. 2000;70:358-366.
24. Passlick B. Initial surgical staging of lung cancer. Lung Cancer. 2003;42:S21-S25.
25. Gajra A, Newman N, Gamble GP, et al. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol. 2003;21:1029-1034.
26. Wu Y, Lin C, Hsu W, et al. Long term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg. 2003;24:994-1001.
27. Ludwig MS, Goodman M, Miller DL, et al. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest. 2005;128:1545-1550.
28. Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small cell lung cancer? Eur J Cardiothorac Surg. 2005:27:680-685.
29. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615-623.
30. Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the new intergroup trial. Clin Lung Cancer. 2006;8:18-21.
31. Wisnivesky JP, Yankelvitz D, Henschke CI. The effect of tumor size on curability of stage I non-small cell lung cancer. Chest. 2004;126:761-765.
32. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257-262.
33. Liu W, Innicenti F, Chen P et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003;9:1009-1012.
34. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol. 2006;1:406-412.
35. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355:570-580.
36. Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in non-small cell lung cancer. N Engl J Med. 2007;356:11-20.